Medicus signs co-development license with Pfizer for CD228V ADC; $1B milestones

Medicus Pharma Ltd.

Exclusive worldwide license from Pfizer to develop/commercialize CD228V, an early-stage antibody-drug conjugate targeting CD228.
Medicus pays $12.0M upfront plus $15.0M on first anniversary; Pfizer pays $2.0M development funding payment.
Pfizer eligible for development, regulatory, and sales milestones exceeding $1.0B total, plus low double-digit tiered royalties.
Medicus retains sole control over development, manufacture, regulatory approval, and commercialization; Pfizer holds option to fund pivotal trials.
Deal effective September 2, 2026; filed as Exhibit 10.1 with redactions for confidential terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.